Huntington Beach, California and Amsterdam (ots/PRNewswire)
Agendia, a world leader in molecular cancer diagnostics, today
announced the appointment of Dr. Albert A. (Al) Luderer to its
Dr. Luderer has more than 30 years of experience in in vitro
medical diagnostics, laboratory medicine and therapeutic development.
Currently, he is the Chief Executive Officer and President of
BioTrove, a privately held company using innovative platform
technologies to dramatically increase throughput for pharmaceutical
screening and genomics research, accelerating drug-discovery
decisions and pipeline development. Dr. Luderer is also the Director
of Light Micronics, Inc. and a Scientific Advisory Board member at
Washington University's Department of Biomedical Engineering, St.
"We are very pleased to welcome Al to our Supervisory Board,"
commented Bernhard Sixt, Ph.D., President and Chief Executive Officer
of Agendia. "As we continue to expand our U.S. activities, Al's
extensive experience and track record of success in the diagnostics
industry will prove extremely valuable to Agendia's growth."
Previously, Dr. Luderer served as Director, President and Chief
Executive Officer of Light Sciences Corporation where he spearheaded
the company's combined business, technical and commercial activities.
Prior to joining Light Sciences Corporation, Dr. Luderer was
President and Chief Operating Officer at bioMerieux, Inc., a world
leader in in vitro diagnostics. From 1987 - 1993, Dr. Luderer was at
Boehringer Mannheim Corporation (now Roche) where he was named Vice
President of Technology Development and Support. He started his work
in the sector at Corning Inc. as a key figure negotiating the joint
venture diagnostic company Ciba Corning (now Siemens Healthcare
Dr. Luderer holds a Bachelor of Arts from Drew University and an
M.S. and Ph.D. from Rutgers University where he was a National
Science Foundation pre-doctoral fellow.
Agendia is at the forefront of the personalized medicine
revolution, striving to bring more effective, individualized
treatments within reach of patients. Building on a cutting edge
genomics platform for tumor gene expression profiling, the company's
tests aim to help physicians more accurately tailor cancer
treatments. The company markets four products, with several new
genomic tests under development. In addition, Agendia collaborates
with pharmaceutical companies to develop highly effective
personalized drugs in the area of oncology. Agendia was awarded the
2008 North American Oncology Clinical Diagnostics Healthcare
Innovation Award by Frost & Sullivan. Agendia is based in Huntington
Beach, California, and in Amsterdam, The Netherlands.
For more information please visit http://www.agendia.com
ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.ch
Media Contacts: Hans Herklots, Head of Corporate Communications,
Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile,
; Valerie Delva, Account Executive, Ricochet
Public Relations, +1-212-679-3300 x131 Office, +1-917-975-3191